Last updated on July 2016

Study to Evaluate Safety Tolerability and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

Brief description of study

The purpose of this study is to compare the safety and effectiveness of four different doses of cytomegalovirus vaccines in healthy adults.

Detailed Study Description

This study is designed to assess safety and immunogenicity of four dose formulations of cytomegalovirus (CMV) vaccine (0.5 μg gB content with aluminum phosphate (alum), 1.0 μg glycoprotein B (gB) content with alum, 2.0 μg gB content with alum, or 1.0 μg gB content (without alum) as compared with placebo in approximately 125 healthy CMV-seronegative volunteer participants between 18 and 40 years of age.

Clinical Study Identifier: NCT02826798

Contact Investigators or Research Sites near you

Start Over

Soren Gantt, MD

Vaccine Evaluation Center
Vancouver, BC Canada
  Connect »

Joanne Langley, MD

Canadian Center for Vaccinology; IWK Health Centre
Halifax, NS Canada
  Connect »

Caroline Quach, MD

McGill University Health Centre - Vaccine Study
Pierrefonds, QC Canada
  Connect »